Diagnosis and treatment progress of primary light-chain amyloidosis
10.3760/cma.j.cn115356-20221228-00363
- VernacularTitle:原发性轻链型淀粉样变诊治进展
- Author:
Yajuan GAO
1
;
Kaini SHEN
;
Jian LI
Author Information
1. 中国医学科学院北京协和医学院 北京协和医院血液内科,北京 100730
- Keywords:
Primary light-chain amyloidosis;
Diagnosis;
Treatment
- From:
Journal of Leukemia & Lymphoma
2023;32(1):22-25
- CountryChina
- Language:Chinese
-
Abstract:
Primary light-chain (AL) amyloidosis is a rare and fatal plasma cell disease. In recent years, the treatment of AL amyloidosis has changed from the era of bortezomib to the era of daratumumab immunotherapy. However, for the treatment choice of advanced-staged patients, how to achieve organ responses at the early stage and how to monitor the disease are questions that need to be further explored. The 64th American Society of Hematology Annual Meeting in 2022 has reported advances in the diagnosis and treatment of AL amyloidosis, which are briefly reviewed in this article.